Omnio

Switzerland-based biotech firm Omnio has teamed-up with Canadian pharmaceutical firm ProMetic to develop a new drug for slow-healing chronic wounds.

The research will be led by Omnio founder and Umea University medical biochemistry and biophysics department researcher Tor Ny.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the deal, the firms will provide funding for clinical studies of a drug based on the blood plasma protein plasminogen.

Plasminogen is a naturally occurring protein, which is synthesised by the liver and circulates in the blood. It is called as plasmin in its activated form, which involves in the lysis of blood clots and wound healing.

“Speeding up the healing of these wounds would mean a lot to the quality of life for the affected patients.”

Under the long-term collaboration, the firms will establish research centre, which will be managed by Omnio in partnership with Umea University.

The research team is planning to start clinical studies with patients in the second half of 2016, which will examine whether the plasminogen will enhance wound healing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The research will determine the role of plasminogen protein in the healing of various slow-healing wounds such as diabetic wounds and bedsore.

Tor Ny said: “My wish is that we will soon have an efficient drug speeding up the treatment and healing of chronic wounds, a large medical problem causing huge suffering. Speeding up the healing of these wounds would mean a lot to the quality of life for the affected patients.

“The troublesome, painful and slow-healing diabetic wounds can even lead to the need of amputating a foot.”

Image: Omnio founder Tor Ny will lead the research on new drug for chronic wounds. Photo: courtesy of Umea University.